DrugPatentWatch Database Preview
Drugs in Development Information for Azacytidine
Development status for investigational drug Azacytidine: Sponsors, patents, clinical trial progress
Azacytidine is an investigational drug.
There have been 124 clinical trials for Azacytidine.
The most recent clinical trial was a Phase 3 trial, which was initiated on August 13th 2019.
The most common disease conditions in clinical trials are Myelodysplastic Syndromes, Preleukemia, and Leukemia, Myeloid, Acute. The leading clinical trial sponsors are National Cancer Institute (NCI), M.D. Anderson Cancer Center, and Celgene Corporation.
Summary for Azacytidine
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 4,774 |
| WIPO Patent Applications | 2,477 |
| Japanese Patent Applications | 4 |
| Clinical Trial Progress | Phase 3 (2019-08-13) |
| Vendors | 90 |
Recent Clinical Trials for Azacytidine
| Title | Sponsor | Phase |
|---|---|---|
| Azacitidine and Venetoclax in Treating Patients With High Risk Acute Myeloid Leukemia in Remission | National Cancer Institute (NCI) | Phase 2 |
| Azacitidine and Venetoclax in Treating Patients With High Risk Acute Myeloid Leukemia in Remission | M.D. Anderson Cancer Center | Phase 2 |
| Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy | Tolero Pharmaceuticals, Inc. | Phase 2 |
Clinical Trial Summary for Azacytidine
Top disease conditions for Azacytidine
Top clinical trial sponsors for Azacytidine
US Patents for Azacytidine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
